Sustainable Growth Advisers (SGA), an investment management company, released its fourth-quarter investor letter for its “U.S. Large Cap Growth Strategy.” A copy of the letter can be downloaded here. In Q4 2025, the Portfolio returned 0.3% (Gross) and 0.2% (Net) compared to 1.1% return for the Russell 1000 Growth Index and 2.7% gain for the S&P 500 Index. Rising volatility, coupled with broadening market leadership, improved the portfolio’s relative performance in the second half of the quarter. In 2025, the Portfolio faced its most challenging years since the firm’s inception in 2003. After a challenging year, the firm is encouraged by the robust growth potential in its portfolio and its historically attractive relative valuation. Progressing further, the portfolio is well-positioned to gain from a shift away from high momentum dynamics in U.S. markets and a broadening of market leadership. Please review the Strategy’s top five holdings to gain insights into their key selections for 2025.
In its fourth-quarter 2025 investor letter, SGA U.S. Large Cap Growth Strategy featured Cooper Companies, Inc. (NASDAQ:COO) as a notable contributor. The Cooper Companies, Inc. (NASDAQ:COO) is a medical device company that operates through CooperVision and CooperSurgical segments. The one-month return of The Cooper Companies, Inc. (NASDAQ:COO) was -0.27%, and its shares lost 12.81% of their value over the last 52 weeks. On February 9, 2026, The Cooper Companies, Inc. (NASDAQ:COO) stock closed at $81.48 per share, with a market capitalization of $16.199 billion.
SGA U.S. Large Cap Growth Strategy stated the following regarding The Cooper Companies, Inc. (NASDAQ:COO) in its fourth quarter 2025 investor letter:
“The Cooper Companies, Inc. (NASDAQ:COO) was a top contributor during the quarter after reporting good operating results and announcing several shareholder friendly developments. In terms of operating results, the company demonstrated progress in alleviating supply constraints for its premium daily silicone hydrogel contact lenses, announced new private label contract wins in the U.S. and Europe, and delivered innovation in myopia control and multifocal lens platforms. In addition, CooperSurgical showed sequential improvement, despite some macro headwinds in Asia Pacific.
